chromosomally balanced translocation?inversion
Conditions
Interventions
Gold Standard:karyotype of amniotic fluid cells, cord blood or abortion tissue
Index test:PGH
Sponsors
Obstetrics and Gynecology Hospital, Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) One of the couple carries a balanced chromosome translocation. Parents of the carriers need to be tested the peripheral blood karyotype at the same time to confirm the translocation as new or hereditary. If the parental sample cannot be obtained, a brother or sister who is also the translocation carrier is optional. If none of the above samples is available, a sample of unbalanced translocation embryos will be used for linkage analysis; 2) Inclusive patients may be those who have a new cycle or those who have completed an ovulation cycle and have normal diploid embryos after PGS testing (no transplantation or no pregnancy after transplantation). It is recommended that the number of blastocysts in the new cycle should be no less than 5, and no less than 2 normal blastocysts in the completed ovulation cycle; 3) If the patient's embryo does not meet the above requirements within one cycle, then a new cycle was optional to cumulate the number of embryos; 4) Embryos detected by PGH are obtained after ICSI.
Exclusion criteria
Exclusion criteria: 1) History of the following diseases: history of thyroid disease, history of adrenal gland disease, history of sexually transmitted diseases and mental disorders; 2) The following abnormalities of the uterus: uterine malformations (single angle uterus, double uterus), untreated mediastinal uterus, uterine adenomyoma, submucosal uterine fibroids, endometrial polyps; 3) Contraindications to assisted reproductive technology or diseases that have a clear impact on pregnancy: including poorly controlled type I, type 2 diabetes; undiagnosed liver or kidney disease or hepatorenal insufficiency; severe anemia History of deep venous thrombosis, pulmonary embolism, cardiovascular and cerebrovascular diseases, uncontrolled high blood pressure, heart disease, suspicious or unequivocal cancer and undiagnosed vaginal bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Karyotype of fetus amniotic fluid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Karyotype of umbilical cord blood;Karyotype of fetus villus; | — |
Countries
China
Contacts
Public ContactCongjian Xu
Obstetrics and Gynecology Hospital of Fudan University
Outcome results
None listed